Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: a report of two cases

Joseph Mansour, Ryan G. Short, Sanjeev Bhalla, Pamela K. Woodard, Amanda Verma, Xavier Robinson, Demetrios A. Raptis

Mallinckrodt Institute of Radiology, Washington University School of Medicine, United States

Cardiovascular Division, Washington University School of Medicine, United States

ARTICLE INFO

Keywords:
Myocarditis
Acute myocarditis
Cardiac magnetic resonance
COVID-19 vaccination
mRNA-COVID-19 vaccine

ABSTRACT

We report two cases of myocarditis, in two young and previously healthy individuals, temporally related to the second dose of the mRNA-COVID-19 vaccine. Both patients developed acute chest pain, changes on electrocardiogram (ECG), and elevated serum troponin within two days of receiving their second dose. Cardiac magnetic resonance (CMR) findings were consistent with acute myocarditis.

1. Introduction

Myocarditis encompasses a broad range of immune processes that may cause functional and/or structural abnormalities in the myocardium. The majority of cases of myocarditis result from viral infections. Non-infectious etiologies of myocarditis are rare and have been reported with systemic inflammatory conditions and after drugs and vaccinations. While myocarditis after vaccination has been reported in the literature, establishing causality remains elusive. Herein, we report two cases of myocarditis after the mRNA COVID-19 vaccine.

2. Case description

2.1. Case 1

A previously healthy 25-year-old man presents to the hospital after receiving the second dose of the mRNA-1273 SARS-CoV-2 immunization (Moderna). On the first day after the second dose the patient developed subjective fever and chills. Six hours after the onset of fevers, the patient noticed substernal chest pain and as result reported to the hospital. His physical examination revealed a fever of 39.1 °C, blood pressure of 129/75 mmHg, pulse of 76 bpm, a respiratory rate of 20, and oxygen saturation of 98% on room air. An electrocardiogram (ECG) revealed diffuse mild concave ST elevations with no reciprocal changes. Initial laboratory evaluation showed an elevated troponin I of 14 ng/mL (normal <0.032 ng/mL), an elevated C-reactive protein (CRP) of 25 ng/mL (normal 0–0.5 ng/mL), and erythrocyte sedimentation rate (ESR) of 25 mm/h (normal <15 mm/h). Nasopharyngeal SARS-CoV-2 PCR was performed twice and was negative; the patient also denies any history of infection with COVID-19. The patient was admitted and underwent coronary angiography that showed normal coronary arteries. An echocardiogram showed normal function and no significant valvular disease; ejection fraction was 55%. Troponin levels continued to rise, peaking at 20.4 ng/mL on hospital day 2 and declined to 9.5 ng/mL by the time of discharge on the morning of hospital day 3, at which point his chest pain had resolved.

The patient was referred for cardiac magnetic resonance imaging (MRI) to evaluate for myocarditis. Cardiac MRI (Fig. 1) was performed on a 3-T scanner [Magnetom Vida, Siemens Healthcare] six days after the second dose of vaccine. Cine images showed normal left ventricular function. Short axis (A) and four-chamber long axis (B) post-contrast inversion recovery images showed subepicardial late gadolinium enhancement in the anterolateral wall of the mid and apical left ventricle. Short axis native T1 (C) and T2 (E) maps showed corresponding increased T1 (1450–1550 ms; normal: 1100–1300 ms) and T2 (54–60 ms; normal: 40–50 ms) signal intensity, respectively. Measured T1 (D) and T2 (F) values of the normal intraventricular septum was 1200–1300 and 43–46 ms, respectively. Per the 2018 Lake-Louis...
A respiratory viral panel was performed and was negative.

2.2. Case 2

A 21-year-old woman with no underlying health conditions presents as a transfer from an outside hospital for chest pain. The patient received the second dose of the mRNA-1273 SARS-CoV-2 immunization (Moderna) vaccine and developed lightheadedness the next day while exercising, such that she was unable to complete her usual exercise routine. Two days after the vaccine, the patient developed sharp retrosternal chest pain that radiated to her left jaw and woke her up from sleep for which she presented to an outside hospital. Her vital signs were normal with a temperature of 36.5 °C, blood pressure of 110/70 mmHg, heart rate of 70 bpm, respiratory rate of 18, and oxygen saturation of 99% on room air. Initial ECG showed diffuse, mild concave ST elevations and PR depressions without reciprocal changes. Her initial laboratory results showed an elevated troponin I of 2.3 ng/mL (normal <0.3 ng/mL), and elevated D-Dimer of 640 ng/mL (normal <500 ng/mL), an ESR of 7 mm/h (normal 1–20 mm/h), and a CRP of 8 ng/mL (normal <10 ng/mL). A nasopharyngeal SARS-CoV-2 PCR was negative and the patient denies past history of infection with COVID-19. The patient reported a family history of long QT syndrome in three of her siblings and her mother for which she has received work-up consisting of echocardiography, a stress test, and genetic testing 4 years prior, all of which were negative; the patient’s QT and QTc at the time of presentation were 384 and 428 ms, respectively.

A CT pulmonary angiogram performed to exclude pulmonary embolism was negative. The coronary arteries were visualized on the CT and appeared normal with no abnormal course or origin. A transthoracic echocardiogram showed a mildly reduced LVEF of 50% with no wall motion abnormalities or significant valvular disease.
Repeat testing showed the troponin I had increased to 4.4 ng/mL. A CMR (Fig. 2) was performed on a 1.5-T scanner [Magnetom Vida, Siemens Healthcare] four days after the second dose to evaluate for possible myocarditis. Cine images revealed normal left ventricular size and function. Short-axis post-contrast images (A) showed subepicardial enhancement in the inferolateral wall at the base. T1 (B) and T2 (D) maps showed corresponding elevated values of 1200 ms for T1 (normal 950–1050 ms), as opposed to 950–980 for the septal wall (C), and 59–63 ms for T2 (normal 45–55 ms) as opposed to 44–48 ms for the septal wall (E). Per the 2018 Lake-Louise criteria, these findings are diagnostic of myocarditis. 2,3 A respiratory viral panel was also performed on this patient and was negative.

The patient’s symptoms resolved the next day and her troponin declined to 1.3 ng/mL. The patient improved clinically and was discharged home on metoprolol.

3. Discussion

On December 11 and December 18, 2020, the United States Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the Pfizer-BioNTech and Moderna mRNA-COVID-19 vaccinations, respectively. A rapid vaccination rollout is now underway and, as of May 31, 2021, more than 285 million doses of both mRNA-COVID-19 vaccines have been administered in the United States alone. 11 These vaccines are generally well-tolerated with mostly self-limited, mild side effects including pain at the injection site, myalgias, and fever, with the reactions potentially being more severe after the second dose. 12,13 In April 2021, the Center for Disease Control and Prevention (CDC) issued recommendations for clinicians regarding reported cases of myocarditis and pericarditis after the mRNA COVID-19 vaccines stating that most cases responded well to medical therapy and rest, and that most occurred in young male adolescents and young adults, more commonly after the second dose. 14 The CDC is currently investigating these reports, but continues to recommend the vaccine for everyone aged 12 years or older. 14

Post-vaccination myocarditis has been reported, most notably after the smallpox vaccine, 15 with a prospective study suggesting a relative risk of clinical myopericarditis of greater than 200-times higher than published background rate. 16 Cases have also been reported after the influenza, tetanus, human papillomavirus, and hepatitis B vaccines, among others 16; however, the association is not as strong as with that of the smallpox vaccine. 15 While the pathophysiology of this entity is unclear, limited endomyocardial biopsy and autopsy case reports show lymphocytic and eosinophilic infiltration adjacent to necrotic myositis suggestive of a maladaptive immune-mediated injury or hypersensitivity reaction. 2,15 The gold standard to determine the underlying etiology in the case of post-vaccination myocarditis would be to perform an endomyocardial biopsy; this was not performed in the cases reported as both patients had rapid clinical improvements.

We have reported two cases of acute myocarditis, both in young, previously healthy individuals with a temporal relation to the second dose of the mRNA-COVID-19 vaccine. In the vaccine trials, younger patients developed a stronger immune response to the vaccine and the second dose produced more severe symptoms when compared to the first. If the myocarditis in these two cases was related to an immune response, this could explain why it occurred after the second dose in both cases. Work-up with a respiratory viral panel was negative for both patients and the panel includes the most common viruses that cause myocarditis in the general population, most notably adenovirus and coxsackie virus. It is important to note, however, that any notion of a causal relationship between the mRNA-COVID-19 vaccine and myocardial inflammation in this case remains speculative. As the rapid vaccine rollout continues, further data may help shed new light on whether myocarditis could be an adverse effect of mRNA-COVID-19 immunization. Both mRNA-COVID-19 vaccines have so far shown to be relatively safe and effective. The benefits of administering the vaccine will still overwhelmingly outweigh the risk of developing myocarditis, if such an association was to be established; however, clinicians and radiologists alike should be aware of this potential relationship.

References

[1] Sagári S, Liu PP, Cooper Jr LT. Myocarditis. Lancet 2012;379(9817):738–47.
[2] Yamamoto H, Hashimoto T, Ohta-Ogo K, et al. A case of biopsy-proven eosinophilic myocarditis related to tetanus toxoid immunization. Cardiovasc Pathol 2018;37: 54–7.
[3] BF JA. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol 2021. In Press.
[4] Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID-19 vaccination. Radiol Case Rep 2021. In Press.
[5] Mouch SA, Rognin A, Hellow E, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine 2021. In Press.
[6] Baetler B, Schaarschmidt F, Strehning C, Schnackenburg B, Maintz D, Bunck AC. A systematic evaluation of three different cardiac T2-mapping sequences at 1.5 and 3T in healthy volunteers. Eur J Radiol 2015;84(11):2161–70.
[7] Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiomyocarvascular magnetic resonance in nonischemic myocardial infarction: expert recommendations. J Am Coll Cardiol 2018;72(24):3158–76.
[8] Luetsens JA, Paron A, Isaak A, et al. Comparison of original and 2018 Lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort. Radiol Cardiothoracic Imaging 2019;1(3):e190010.
[9] Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. Morb Mortal Wkly Rep 2020;69(50): 1922.
[10] Oliver SE. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep 2020;69:69.
[11] Trends V. COVID Data Tracker. 2021.
[12] Baden LR, El Sahly HM, Einik B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384(5):403–16.
[13] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603–15.
[14] Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. Retrieved from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html#2021.
[15] Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS), 1990–2018. Vaccine 2021;39(5):839–45.
[16] Engler RJ, Nelson MR, Collins Jr LC, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One 2015;10(3):e0118283.
[17] Mei R, Raschi E, Forconi E, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and pericarditis after immunization: gaining insights through the vaccine adverse event reporting system. Int J Cardiol 2018;272:183–4.
[18] Murphy JG, Wright BS, Bruce GK, et al. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 2003;362(9393):1378–80.